Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

Phase 1/2 Completed 108 enrolled Southern California Desert Retina Consultants, MC

RandomizedParallel-groupSingle-blindPrevention

Summary

This study will determine whether quarterly injections of Ranibizumab may prevent eyes with dry age-related macular degeneration from progressing to wet age-related macular degeneration (AMD).

Timeline

Start: 2014-09-17
Primary completion: 2020-07-09
Completion: 2020-07-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

Summary

Timeline

Drugs

Indications